Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ORIN1001 |
Synonyms | |
Therapy Description |
ORIN1001 inhibits IRE1 and blocks XBP1 activation, which potentially decreases tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 1092)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ORIN1001 | ORIN-1001|ORIN 1001 | ORIN1001 inhibits IRE1 and blocks XBP1 activation, which potentially decreases tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 1092)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03950570 | Phase I | ORIN1001 + Paclitaxel ORIN1001 | ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | Active, not recruiting | USA | 0 |